Quick search:
Result Content Outlet Published Research
Result Content Outlet Published Research
1 Roche MS Trial Woes Highlight Current Perils of Reliance on Eastern Europe BioSpace 24 days ago
2 AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 for the Treatment of Advanced Parkinson's Disease Investing News Network 4 hours ago
3 Janssen Showcases Recent Data in Relapsing Multiple Sclerosis at the 2021 European Committee for Treatment and Research in Multiple Sclerosis Congress PR Newswire 8 months ago
4 TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis BioSpace 7 months ago
5 Updated MS Guidelines Advocate Earlier, More Aggressive Treatment Medscape 7 months ago
6 AB Science reports its revenues for the year 2021 and provides an update on its activities GlobeNewswire 21 days ago
7 Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) USA English 7 months ago
8 The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VRT, VLTA and ABBV Investing News Network 3 hours ago
9 Pfizer and Biohaven's VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine Pfizer 23 days ago
10 Ultomiris met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder AstraZeneca 15 days ago
11 Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire 18 days ago
12 Fierce Pharma Asia—Hengrui's global plan; Merck, Kelun's $1.4B cancer deal; Dr. Reddy's Russia business FiercePharma 3 hours ago
13 AbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week® Investing News Network 4 days ago
14 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Lucid, AbbVie, Playstudios, and IBM and Encourages Investors to Contact the Firm Investing News Network 2 days ago
15 #ECTRIMS2021 – Quitting Smoking May Help Slow MS Progression Multiple Sclerosis News Today 7 months ago
16 #ECTRIMS2021 – Cortical Lesions Predict Long-term Cognition... Multiple Sclerosis News Today 7 months ago
17 ROSEN, A LEADING LAW FIRM, Encourages AbbVie Inc. Investors to Secure Counsel Before Important June 6 Deadline in Securities Class Action ABBV 2 days ago
18 Teva faces lawsuit from Israel over unpaid Copaxone royalties FiercePharma 9 days ago
19 Novartis presents new four-year data on efficacy and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis Novartis 2 months ago
20 ECTRIMS: Roche touts 8-year Ocrevus data to defend multiple sclerosis leadership FiercePharma 7 months ago
21 Looking Beyond the Typical Measures of MS Diagnosis Medscape 6 months ago
22 Novartis CEO: Leqvio, Pluvicto off to good US launch FiercePharma 24 days ago
23 Why does Roche think 2022 could end up flat despite 11% Q1 jump? FiercePharma 25 days ago
24 Biogen CEO's 2021 pay remains level despite Aduhelm tribulations FiercePharma 21 days ago
25 Merck Completes Enrolment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021 Business Wire 8 months ago
26 New genetic clues on multiple sclerosis risk Science Daily 4 months ago
27 ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action ABBV 4 days ago
28 Dimethyl Fumarate Versus Teriflunomide for Relapsing MS Medscape 7 months ago
29 #ECTRIMS2021 ATA188 Benefits in SPMS, PPMS Hint at Remyelination 8 months ago
30 Ofatumumab Safety Data Reinforced By Multi-Year Study in Patients With Relapsing Multiple Sclerosis Pharmacy Times 7 months ago
31 Virtual Care May Help Multiple Sclerosis Patients Even After the Pandemic Medpage Today 7 months ago
32 Targeting EBV-Infected Cells To Treat Multiple Sclerosis Technology Networks 3 months ago
33 UPenn Neurologist Wins Barancik Prize for Innovation in MS Research Multiple Sclerosis News Today 3 months ago
34 Which Agent Best for Neuromyelitis Optica? Medscape 7 months ago
35 Stem Cell Transplant Benefits in Secondary Progressive MS Medscape 7 months ago
36 Frequent MRI May Spot Active Secondary Progressive MS More Quickly Medpage Today 7 months ago
37 New MAVENCLAD® Data at ACTRIMS Forum 2022 Show Favourable Efficacy Outcomes Versus Other Oral DMTs and Lower Occurrence of Further Relapses or Disability Progression Business Wire 3 months ago
38 New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerging Research on Disease Progression | Biogen Biogen 2 months ago
39 Temelimab Proves Safe at Highest Dose for Multiple Sclerosis in Phase 2 Topline Data Neurology Live 2 months ago
40 Mitsubishi Tanabe scores FDA nod for oral version of its ALS drug Radicava FiercePharma 7 days ago
41 AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the Swedish Medical Products Agency GlobeNewswire 4 months ago
42 The lower basal metabolic rate is associated with increased risk of osteosarcopenia in postmenopausal women BMC Women's Health 6 days ago
43 Year in Review: Multiple Sclerosis | MedPage Today Medpage Today 6 months ago
44 Clene Nanomedicine Presents Blinded Interim Update from VISIONARY-MS and Positive Results from REPAIR-MS Phase 2 Clinical Trials GlobeNewswire 7 months ago
45 Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis Business Wire 7 months ago
46 New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis Yahoo Finance 7 months ago
47 ECTRIMS-ACTRIMS 2017 Medscape 5 years ago
48 The experience of participating in an internet-based cognitive behavioral therapy program among patients with cardiovascular disease and depression: a qualitative interview study BMC Psychiatry 25 days ago
49 New peer-reviewed research shows no increased risk of serious COVID-19 infections in Kesimpta® (ofatumumab)-treated adults with multiple sclerosis Novartis 2 months ago
50 TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results GlobeNewswire 3 months ago
51 Positive safety data for long-term use of MS drug Kesimpta - pharmaphorum 7 months ago
52 Smoking, Drinking Tied to Increased MS Risk, More Severe Symptoms Medscape 2 months ago
53 Janssen Demonstrates Its Commitment to Advancing Transformative Solutions for Multiple Sclerosis at ACTRIMS Forum 2022 PR Newswire 3 months ago
54 New Real-World MAVENCLAD® Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients Business Wire 7 months ago
55 Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial The Lancet 8 days ago
56 AB Science OK'd to Start Masitinib Phase 3 Trial in Progressive MS Multiple Sclerosis News Today 5 months ago
57 Current Strategies in Treating Cytokine Release Syndrome | ITT Dove Medical Press 2 days ago
58 Rapid Progress in ALS: A Reflection of Advances in Neuromuscular Disorder Care Neurology Live 8 days ago
59 Rituximab More Effective Than Other MS Treatments? Medscape 7 months ago
60 Octave Bioscience Building Evidence Base for Multiple Sclerosis Test to Support Clinical Launch 360Dx 3 months ago
61 CNM-Au8 Raises Brain Energy Metabolism of RRMS Patients in Trial Multiple Sclerosis News Today 10 months ago
62 MS News That Caught My Eye: COVID-19 Booster, EBV Treatment, Vitamin D Multiple Sclerosis News Today 4 months ago
63 Low Neutralizing Antibody Incidence, High Antidrug Antibody Rates Observed in MS With Ublituximab Treatment Neurology Live 3 months ago
64 European Commission approves PONVORYTM (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features Business Wire 12 months ago
65 CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis GlobeNewswire 8 months ago
66 Experts clarify subtypes of multiple sclerosis to improve care and clinical trials EurekAlert 2 years ago
67 Atara Biotherapeutics: Developing personalized, off-the-shelf therapies for multiple sclerosis 9 months ago
68 Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update 5 hours ago
69 Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Is Safe, Efficacious Over Long-Term Neurology Live 2 months ago
70 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022 | European Medicines Agency European Medicines Agency | 3 months ago
71 The Latest on Multiple Sclerosis and COVID-19 Vaccines Medscape 8 months ago
72 Roche says hola to Hispanic, Latinx multiple sclerosis communities FiercePharma 2 months ago
73 BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update BioSpace 2 months ago
74 Ublituximab as Relapsing MS Therapy Under FDA Review Multiple Sclerosis News Today 5 months ago
75 New 4-Year Data Show Genentech's Enspryng (satralizumab-mwge) Significantly Reduces Debilitating Relapses in People With Neuromyelitis Optica Spectrum Disorder Business Wire 7 months ago
76 Masitinib Slows Disability Progression in PPMS, Non-active SPMS Multiple Sclerosis News Today 3 months ago
77 European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm 3 years ago
78 Novartis peer-reviewed safety and tolerability data further strengthens Kesimpta's (ofatumumab) favorable benefit-risk profile in patients with relapsing multiple sclerosis Novartis 3 months ago
79 New Consensus Guideline on Clinical MRI Use in MS Medscape 7 months ago
80 Progressive MS Phase 3 Trial of Masitinib OK'd to Start in Sweden Multiple Sclerosis News Today 3 months ago
81 MS Therapy Candidate NVG-291 Cleared to Enroll 2nd Volunteer Group Multiple Sclerosis News Today 2 months ago
82 Nanocrystals Boost Bioenergetics and Restore Neuronal Health Genetic Engineering & Biotechnology News 7 months ago
83 Azurity bags FDA nod for grape-flavored multiple sclerosis drug FiercePharma 3 months ago
84 More Results for Ozanimod: DAYBREAK Data, Cognition and Gray Matter, Biomarker for Relapsing MS Managed Markets Network 3 years ago
85 Qynapse to present new evidence on the value of QyScore® for the diagnosis and monitoring of multiple sclerosis at ACTRIMS Forum 2022 PR Newswire 3 months ago
86 Alterations of host-gut microbiome interactions in multiple sclerosis The Lancet 4 months ago
87 New PBS Listings Will Lower Cost of MS Therapy Kesimpta in Australia Multiple Sclerosis News Today 8 months ago
88 Link Between Lesion Location and Obstructive Sleep Apnea in Multiple Sclerosis Neurology Advisor 3 years ago
89 Safety Concern With Fingolimod to Ocrelizumab Switch in MS Medscape 2 years ago
90 Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis GlobeNewswire 1 year ago
91 MS Therapy Fampyra Not Eligible To Be Added to NHS for England: NICE Multiple Sclerosis News Today 5 months ago
92 New Data Shed Light on Racial, Ethnic Diversity in MS Medscape 1 month ago
93 WVU research suggests interrupting immune response improves multiple sclerosis outcomes Charleston Gazette-Mail 1 month ago
94 Tackling Secondary Progressive Multiple Sclerosis Early on Benefits Patients in a Number of Ways Managed Healthcare Executive 1 year ago
95 Dr John Corboy on Research About Stopping Disease-Modifying Therapies for Multiple Sclerosis Managed Markets Network 2 years ago
96 #ECTRIMS2019 Is Rituximab a Reasonable Option for MS Patients? 3 years ago
97 Longitudinal relationships between disability and gait characteristics in people with MS | Scientific Reports 2 months ago
98 Need to Know: What Is Acthar Gel? Multiple Sclerosis News Today 2 years ago
99 After a year as Merck KGaA healthcare CEO, Guenter reflects on I-O bispecific flop, spots new multiple sclerosis strategy FierceBiotech 3 months ago
100 Three EU Tecfidera Generics Recommended As Biogen Battles For Exclusivity Generics Bulletin 3 months ago